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Background: The etiology and the molecular basis of lung adenocarcinomas (LuADs) in nonsmokers are currently
unknown. Furthermore, the scarcity of available primary cultures continues to hamper our biological understanding
of non-smoking-related lung adenocarcinomas (NSK-LuADs).
Patients and methods:Weestablishedpatient-derivedcancercell (PDC) cultures frommetastaticNSK-LuADs, including twopairs
of matched EGFR-mutant PDCs before and after resistance to tyrosine kinase inhibitors (TKIs), and then performed whole-exome
and RNA sequencing to delineate their genomic architecture. For validation, we analyzed independent cohorts of primary LuADs.
Results: In addition to known non-smoker-associated alterations (e.g. RET, ALK, EGFR, and ERBB2), we discovered novel fusions
and recurrentlymutatedgenes, includingATF7IP, a regulatorofgeneexpression, thatwas inactivated in5%ofprimaryLuADcases.
Wealso foundgermlinemutationsatdominant familiar-cancergenes, highlighting the importanceofgeneticpredisposition in the
origin of a subset ofNSK-LuADs. Furthermore, therewas anover-representationof inactivatingalterations atRB1,mostly through
complex intragenic rearrangements, in treatment-naive EGFR-mutant LuADs. Three EGFR-mutant and one EGFR-wild-type
tumors acquired resistance to EGFR-TKIs and chemotherapy, respectively, and histology on re-biopsies revealed the
development of small-cell lung cancer/squamous cell carcinoma (SCLC/LuSCC) transformation. These features were consistent
with RB1 inactivation and acquired EGFR-T790Mmutation or FGFR3eTACC3 fusion in EGFR-mutant tumors.
Conclusions:We found recurrent alterations in LuADs that deserve further exploration. Our work also demonstrates that a
subset of NSK-LuADs arises within cancer-predisposition syndromes. The preferential occurrence of RB1 inactivation, via
complex rearrangements, found in EGFR-mutant tumors appears to favor SCLC/LuSCC transformation under growth-
inhibition pressures. Thus RB1 inactivation may predict the risk of LuAD transformation to a more aggressive type of
lung cancer, and may need to be considered as a part of the clinical management of NSK-LuADs patients.
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Lung cancer (LC) is the primary cause of death from cancer in
most Western countries,1 with adenocarcinomas (LuADs),
squamous cell carcinomas (LuSCCs), and small-cell lung cancer
(SCLC) themost commonly diagnosed types. Although tobacco
smoking is themain risk factor for LC, 10%e20% of LuAD cases
will arise in nonsmokers.2 LC among nonsmokers is signifi-
cantly more common in women than men,2 and has someVolume 31 - Issue 2 - 2020
E. Pros et al. Annals of Oncologydistinctive gene alteration features, including a lower muta-
tional burden and activating gene alterations at growth factor
receptors, for example, ALK, EGFR, ERBB2, ROS1, and RET, that
do not coexist.3,4 The presence of these mutations confers
therapeutic benefits because these molecules are amenable
to inhibition by specific tyrosine kinase inhibitors (TKIs).5 By
contrast, LuADs in smokers have a different gene alteration
profile with simultaneous alterations in several known cancer
genes (e.g. KRAS, STK11) and are more likely to have a greater
mutational burden.4,6 The few genome-wide studies of LuADs
from nonsmokers have focused on EGFR-mutant tumors and
have yielded promising information about the underlying ge-
netics of these tumors, including concurrent mutations of
potential biological relevance.7,8
Studies of cancer cell lines have been responsible for some
major contributions to our understanding of LC biology and
pathogenesis as well as providing useful tools for trans-
lational research.9,10 Cultured tumor cells, which accurately
represent tumor cells in vivo, are basically populations of
pure tumor cells without admixed stromal or inflammatory
cells that can mask the mutations present in the tumor cells.9
Although >250 LC cell lines from all histopathological sub-
types are available, there are very few derived from
nonsmoker LuAD patients, which has limited our under-
standing of the biology of these tumors. Thus a larger set of
LC cell lines with these characteristics is required if we are to
gain a deeper understanding of the molecular basis of lung
carcinogenesis in nonsmoker individuals and be able to
analyze the mechanisms that drive resistance to TKIs.
Here, we have established a repertoire of patient-derived
cancer cell (PDC) cultures from non-smoking-related LC
patients and performed an integrated genomic (i.e. somatic
and germline gene alterations and expression profile) and
molecular analysis.PATIENTS AND METHODS
Tumor samples and generation of LC cell cultures
PDC cultures (n ¼ 13) were established from the malignant
pleural effusions of 11 different LuAD patients, from the
Catalan Institute of Oncology (supplementary Table S1, avail-
able atAnnals ofOncologyonline). Cancer cellswere isolated as
previously described (supplementary methods, available at
Annals of Oncology online).10 Validation cohorts consisted, in
most cases, in tumor specimens collected at the time of surgery
(stage IeIII tumors) or fromdiagnostic biopsies (supplementary
Figure S1A, supplementary Table S2, and supplementary
methods, available at Annals of Oncology online). Normal
DNA was obtained from blood or adjacent normal tissue.
Written consent was obtained and procedures were approved
by the Institutional Review Board of Institut d’Investigacio
Biomedica de Bellvitge (IDIBELL).Whole-exome sequencing, RNA sequencing, and data
analysis
Whole-exome sequencing (WES), RNA-seq, and data anal-
ysis were carried out at the Spanish National GenomeVolume 31 - Issue 2 - 2020Analysis Center (CNAG, Barcelona, Spain; supplementary
methods and supplementary Table S3, available at Annals
of Oncology online).11Multiplex ligation-dependent probe amplification and RB1
panel for mutational screenings
Multiplex ligation-dependent probe amplification was used to
test for complex rearrangements at RB1. For the mutational
analysis a custom-designed RB1 panel was used (http://
sequencing.roche.com/products/software/nimbledesign-soft
ware.html; supplementary methods, available at Annals of
Oncology online).Statistical analysis
Analysis consisted of chi-square, two-tailed unpaired Stu-
dent’s t-test, ManneWhitney test, and analysis of variance,
as appropriate. Continuous variables are summarized as
means and standard deviations.
RESULTS
Establishment of a PDC repertoire from non-smoking-
associated LCs and assessment of genome-wide
characteristics
We established PDCs cultures from the discarded pleural
liquid drained from 11 non-smoking-related lung adeno-
carcinoma (NSK-LuAD) patients (supplementary Table S1
and supplementary Figure S1B, available at Annals of
Oncology online). NSK-LuADs were defined as those ade-
nocarcinomas of the lung that fulfilled at least one of the
following conditions: (i) occur in a never-smoker or >25-
year ex-smoker, (ii) bear EGFR or ALK alterations, or (iii)
arise in individuals 48 years of age. The features of the
patients and tumors including prior knowledge of the ge-
netics of the tumors are described in supplementary
Table S1 (available at Annals of Oncology online).
We performed WES and RNA-seq and found a mutation
frequency in coding regions that ranged from 76 to 499
across the PDCs (Figure 1A). The only current smoker,
despite being relatively young (46 years), developed the
tumor with the highest mutation frequency (n ¼ 499). The
relative frequency of C:G>A:T transversions in the PDCs
was relatively low (<20%) and similar to that reported for
LuAD in nonsmokers.3 Following pre-established criteria
(supplementary Figure S2A, available at Annals of Oncology
online), we selected the genes affected by somatic non-
silent alterations (supplementary Tables S4eS6, available
at Annals of Oncology online). Genetic activation was found
at several known oncogenes, including high-level amplifi-
cation involving MDM2, whereas tumor-suppressor genes
(TSGs) exhibited biallelic inactivation, such as TP53 and RB1
(Figure 1A). Alterations at RB1 were through homozygous
deletions and appeared in the three EGFR-mutant PDCs. The
PDC10 did not express TP53 and a detailed analysis revealed
the presence of a TP53/FXN transcript, which confirmed a
complex mechanism of TP53 inactivation (supplementary
















Figure 1. Somatic gene alterations detected by whole-exome sequencing (WES) and RNA-seq analysis of the non-smoking-related lung adenocarcinoma (NSK-
LuAD) cells. (A) Top panel, histograms display the type of base-pair substitution and the exonic mutation burden (nonsynonymous, nonsense, splicing, and indel
mutations) from the WES analysis referred to each sequenced patient-derived cancer cells (PDCs). Bottom panel, oncoplot depicting the alterations, in well-
established cancer genes, in the indicated lung cancer cell lines. (B) Selection of candidate tumor-suppressor genes (TSGs) and oncogenes (ONCs; from
supplementary Table S7, available at Annals of Oncology online) and the related functions involved, as indicated. (C) Top panel, identification, by RNA-seq, of three
in-frame fusion transcripts in the indicated cells. Bottom panel, representation of the gene expression levels of each of the genes involved in the fusions, in all the
PDCs from the current study. (D) Venn diagram indicates the TSGs and ONCs from the current study that overlap the Cancer Gene Census (CGC), available in the
COSMIC database (list of overlapping genes included in the two squares). ZCCHC8 is a TSG candidate that is listed as an ONC in the CGC and NRG1 is an ONC
candidate that is listed as a TSG in the CGC. (E) Schematic representation of ATF7IP, SETD2, and MB21B2 proteins and location of the inactivating mutations (for
ATF7IP and SETD2) and of the point mutations (for MB21D2) found in our cohorts of LuADs (PDCs and primaries; n [ 33) and in two TCGA cohorts (http://www.
cbioportal.org/). The mutations detailed are from the current work. (F) Distribution of the missense and truncating mutations, for each indicated gene, in the LuAD
and lung squamous cell carcinoma (LuSCC) cohorts from TCGA. *P <0.05; ***P <0.005.
EX, ex-smoker; NS, nonsmoker; SK, current smoker; TCGA, The Cancer Genome Atlas.
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Following an established criterion11 we filtered our candi-
dates (from supplementary Tables S4eS6, available at Annals
of Oncology online) to search for additional oncogenes and
TSGs. The analysis yielded 27 TSG and 109 oncogene candi-
dates that coded for proteins involved in different functions
(Figure 1B and supplementary Table S7, available at Annals of
Oncology online). The candidates include three fusions with
one of the partners overtly overexpressed (Figure 1C).
Overexpression of these genes was confirmed in LCs from
The Cancer Genome Atlas (TCGA) database (supplementary
Figure S3, available at Annals of Oncology online). The
TFGeADGRG7 fusion was also in the DNA from the blood, as
previously reported.12276 https://doi.org/10.1016/j.annonc.2019.09.001Next, we compared our selected candidates (supplementary
Table S7, available at Annals of Oncology online) and the bona
fide TGS and oncogenes with the COSMIC-Cancer Gene Census
(CGC).13 One-third of the TSGs and one-fifth of the oncogenes
found in this study were present in the CGC (Figure 1D).
To determine whether the mutations in the candidates
were recurrent, we scrutinized the WES data in the inde-
pendent cohort of stages IeIII primary NSK-LuADs
(supplementary Table S2 and supplementary Figure S1A,
available at Annals of Oncology online). We found inacti-
vating alterations at ATF7IP, GBP3, SETD1B, and SETD2; the
latter two were in the CGC. The recorded nonsynonymous
mutations at the SETD2 and ATF7IP genes in the TCGA were
>5% for non-small-cell lung cancer, half of which are listedVolume 31 - Issue 2 - 2020
E. Pros et al. Annals of Oncologyas truncating (Figure 1E). This is above the threshold
(>20%) proposed for TSG candidates.14 Inactivating muta-
tions at these genes were more common in LuADs than in
LuSCCs (Figure 1F), although we could not conclude a pre-
dominance in nonsmokers (data not shown). Finally, a
heterozygous change, p.Gln311Glu, at MB21D2 found at
PDC11 was found in 1% of the LuADs and LuSCCs of the
TCGA (Figure 1E and F). The mutation affects a conserved
amino acid within the Mab-21 domain (supplementary
Figure S4, available at Annals of Oncology online). The
change appeared at similar frequencies in head and neck
squamous cell carcinomas and in bladder urothelial carci-
nomas, but not in other common cancers.
RB1 inactivation by intragenic complex rearrangements
predominates in EGFR-mutant LuADs
The three EGFR-mutant PDCs presented inactivation of RB1,
all by deletions involving one or more exons. Although a
selective presence of RB1 mutations in LuADs from EGFR-
mutant tumors has been observed,9,15 the intragenic com-
plex rearrangements (ICRs) have not been examined. Here,
we scrutinized an independent cohort of LuADs for muta-
tions and ICRs at RB1 (supplementary Table S2, available at
Annals of Oncology online). Alterations at RB1 were found
in seven (14%) of the tumors analyzed, six of which con-
sisted of ICRs (Figure 2A and B). The frequency of RB1
inactivation was significantly higher in the EGFR-mutant
(41%) than in the EGFR-wild-type (1%) tumors. The former




Figure 2. RB1 is preferentially inactivated, mostly by intragenic complex rearrangem
of the structure of RB1, with all its corresponding exons. Bottom panels, ratio chart
intragenic deletions of various exons in two tumors and the duplication of intron 1
rectangles indicate the exons that had experienced intragenic homozygous deletion
spanning point mutations (above) and the ICR (lines below) found in the screening.
lung cancers (single asterisk) or the type of RB1 alterations among small-cell lung ca
asterisk) (supplementary Figure S1A, available at Annals of Oncology online).
E, exon; I, intron; LuAD, lung squamous cell carcinoma; NS, not significant.
Volume 31 - Issue 2 - 2020lines from the Cancer Cell Line Encyclopedia database.
However, whereas in SCLC RB1 was inactivated mostly
through point mutations, it was preferentially achieved via
ICR in EGFR-mutant LuADs (Figure 2C).
SCLC and LuSCC transformation in RB1-inactivated LuADs
One EGFR-mutant/RB1-inactivated tumor (patient #4)
switched from LuAD to mixed SCLC/LuSCC at clinical pro-
gression to EGFR-TKI, which prompted us to look for addi-
tional LuADs that had transformed to SCLC/LuSCC.
Patient #4 was diagnosed with an EGFRex19-mutant
LuAD with lung, pleural, and brain metastasis. A malignant
pleural effusion was obtained before afatinib treatment and
PDC4 was derived. After an initial partial response, she
developed brain and lung progression (Figure 3A). The
genotyping of a liquid biopsy discarded the EGFR-T790M
mutation and carboplatinepemetrexed treatment was
administered, achieving a remarkable shrinkage of the lung
lesion but an enlargement of a mediastinal lymph node. A
pleural biopsy after relapse revealed LuSCC morphology and
a biopsy from the lymph node showed combined SCLC/
LuSCC features and the ICR at RB1 (Figure 3B and C).
Patient #76, diagnosedwith an EGFRex19-mutant LuAD and
bone metastasis, underwent treatment with dacomitinib,
showing a partial response. At progression, the EGFR-T790M
mutation was detected in a liquid biopsy and the patient was
treated with osimertinib. After the patient progressed with
new bone/liver metastasis, the analysis of multiple genes in a
liquid biopsy identified an RB1 mutation (p.Leu683fs),LuADs (EGFR-mutant)
n = 17
LuADs (EGFR-wild type)








P = NS (*) P < 0.001 (*)
P < 0.0001 (**)
ents (ICRs), in EGFR-mutant LuADs. (A) Upper panel, schematic representation
s of the multiplex ligation-dependent probe amplification (MLPA) depicting the
in one of the tumors. An appropriate normal control is also included. The black
or duplications. (B) Schematic representation of the RB1 structure to show the
(C) Pie charts comparing the frequency of RB1 alterations in the three groups of
ncer cells (from Cancer Cell Line Encyclopedia) and EGFR-mutant LuADs (double
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available at Annals of Oncology online), but not the EGFR-
T790M. A liver biopsy showed the same genotype along with
SCLC morphology (Figure 3A).
Patient #59 was diagnosed with locally advanced, EGFR-
wild-type LuAD and underwent concurrent chemo-
radiotherapy. After 32 months, the disease progressed to
the brain and she underwent surgery and focal radio-
therapy. The metastatic lesion exhibited LuSCC features
(TTF1/CK7/CK20-positive immunostaining). Five months
later, after lymph-node progression, a biopsy showed a
mixed SCLC/LuSCC and a duplication of various exons at RB1
(Figure 3C). The patient received platinum-based chemo-
therapy but developed bone metastasis, which showed
LuSCC features. There was no DNA left from the original
primary tumor to determine the baseline status of RB1 in
patients #76 and #59.
Finally, patient #5 was diagnosed with an EGFRex19-
positive LuAD with multiple metastases. Nine months after
treatment with gefitinib, the disease progressed and the
analysis of liquid and pleural biopsies showed LuAD features
but not EGFR-T790M mutation. After treatment with afa-
tinib, the disease rapidly progressed and no additional bi-
opsies were taken (Figure 3A). Two PDCs were derived from
this patient: after diagnosis at 8 months (PDC5) and at 11
months (PDC5.2), following progression to afatinib. Both
PDCs carried identical alteration at RB1, and PDC5.2 showed
SCLC/LuSCC characteristics and an FGFR3eTACC3 fusion
(details in the following section).Acquired resistance to EGFR-TKI shows evidence of
combined SCLC and LuSCC features and additional gene
alterations
The PDC4.2 and PDC5.2, derived after the patients progressed
to EGFR-TKIs, had acquired changes in morphology (Figure 4A).
In cell culture, the PDC5.2 samples were less sensitive to erlo-
tinib and afatinib than the pretreatment counterpart (Figure 4B
and supplementary Figure S5B, available at Annals of Oncology
online). Despite reduced EGFR levels, both cells maintained the
ability todecreasepEGFRandblockextracellular receptor kinase
phosphorylation upon treatment (Figure 4C and D and
supplementary Figure S5C, available at Annals of Oncology on-
line). Thus the acquired resistance to the TKI in these cells does
not involve changes in EGFR activity. To study the molecular
mechanisms underlying resistance to the TKIs in these tumors,
we performed WES and RNA-seq on PDC4.2 and PDC5.2 and
compared them with their pretreated counterparts. WES
confirmed theEGFRmutations and the ICRs atRB1 andRNA-seq
yielded evidence of overexpression of transcripts that are
characteristic of SCLCs and LuSCC lineages16 (Figure 4E). After
filtering, we identified four and 11 acquired alterations in
PDC4.2 and PDC5.2, respectively (supplementary Table S8,
available at Annals of Oncology online), including an FGFR3e
TACC3 fusion in PDC5.2, which is involved in acquired resistance
to EGFR-TKIs (supplementary Figure S5D, available at Annals of
Oncology online). This fusion may explain the LuSCC differenti-
ation features observed in these cells.MDM2was also strongly278 https://doi.org/10.1016/j.annonc.2019.09.001reamplified in PDC5.2, although its involvement in resistance to
TKI is unknown (supplementary Figure S5E, available at Annals
of Oncology online).Germline mutations in cancer predisposition genes in NSK-
LuADs
The somatic mutation at TP53 found in PDC4 was heterozygous
and the inspection of the Integrative Genomics Viewer allowed
us to identify another mutation (p.Arg158His) in the germline
(DNA from the blood).Themother of patient #4, also diagnosed
with LuAD, carried the germline TP53 mutation, making it
consistent with LieFraumeni syndrome. Both patients showed
EGFRmutations in their tumors. This observation prompted us
to scrutinize an independent cohort of 27 primaryNSK-LuADs to
search for cancer predisposition variants. The germline of these
patients was examined using WES or direct Sanger sequencing
of TP53, BRCA1, and BRCA2 (supplementary Table S2, available
at Annals of Oncology online). Further, we scrutinizedWES data
from TCGA cohorts and observed changes at dominant and at
recessive cancer predisposition genes, affecting 6% of the NSK-
LuADs (Table 1). Two changes, the p.Asn588Ser at BRCA2 and
the p.Arg290His at TP53, are listed as variant of unknown sig-
nificance (VUS). In the tumor, the VUS at TP53was concomitant
with a somatic mutation (p.Cys141Tyr) without loss of hetero-
zygosity. The p.Arg290His variant has been reported to appear
somatically in human cancer and to be inactivating.17 Finally,
heterozygous pathogenic mutations were found in the BLM,
FANCL, andWRN, associated with the Bloom, Fanconi anemia,
and Werner syndromes, respectively, when biallelically inacti-
vated in the germline.DISCUSSION
This comprehensive analysis of PDCs fromNSK-LuADs revealed
alterations in well-established non-smoking-associated drivers
and novel potential TSGs and oncogenes. ATF7IP, a transcrip-
tional modulator involved in heterochromatin formation,
through the stabilization of the histone methyltransferase
SETDB1,18 was found to be inactivated in 5% of the LuADs,
making its potential involvement as a TSG worthy of further
investigation. Moreover, theMB21D2 gene, for which there is
almost no available information, was found mutated in a
hotspot which is of interest and suggests an oncogenic role.
MB21D2may be related toMB21D1which codes for the cyclic
guanosine monophosphateeadenosine monophosphate syn-
thase, functionally associated with the immunity-related pro-
tein STING.19
Our results are firm evidence that RB1 inactivation is a
common event in EGFR-mutant LuADs and that ICR is the
preferred mechanism. The reasons why RB1 inactivation is
more common in EGFR-mutant LuADs than in other type of
LuADs, and why the main alteration is ICRs, instead of point
mutations, as in SCLC, remain to be ascertained. EGFR-
mutant tumors may be more prone to double-strand breaks
(DSBs) or carry deficiencies in the repair of DSBs. The al-
terations at EGFR, by insertions or deletions at exons 19 and
20, would be consistent with this type of dysfunction.Volume 31 - Issue 2 - 2020
Figure 3. Dissection of the molecular events underlying SCLC/LuSCC transformation. (A) Treatment received and sample extraction timelines (m, months) for each
indicated patient. On the basis of the identification of EGFR-mutant tumors, patients were treated with a first-line EGFR-TKI. Patient #4: afatinib (AFA), carbo-
platin/pemetrexed (ChT); Patient #76: dacomitinib (DAC), osimertinib (OSI), and cisplatin/etoposide (ChT). Patient #59: concurrent chemoradiotherapy (cChT-RT),
brain surgery plus radiotherapy (surgery/RT), platinum-based ChT (ChT). Patient #5: gefitinib (GEF) and afatinib (AFA). Genotyping of EGFR in patients #4, #5, and
#59 and in the liquid biopsy of patient #76 (at 23 months) was performed using the cobas EGFR Mutation Test v2 (Roche Molecular Diagnostics, Basel,
Switzerland). RB1-mutation at 32 months in patient #76 was found using Guardant360 (Illumina HiSeq, Guardant Health, Redwood City, CA) and the RB1-ICR in
patients #4 and #59, using multiplex ligation-dependent probe amplification (MLPA). (B) Upper panel: diagnostic computed tomography scan (CT scan) of patient
#4. Left, massive left pleural effusion prior to treatment with TKIs (pretreatment); middle, pleural effusion reduction upon TKI treatment (post-treatment); right,
disease progression evident from a new lesion suggesting a mediastinal lymph node that extends toward the left pulmonary artery and extensive loculated pleural
effusion (resistant). Lower panels: Hematoxylineeosin (HE) staining and immunostainings of P63 and of synaptophysin (SYP) of the biopsies from the lymph node
(mixed LuSCC/SCLC) and pleural mass (LuSCC; 15 months after initial diagnosis) after resistance to the TKI (resistant; magnification, 3400). (C) Upper panel,
schematic representation of the structure of RB1, with all its corresponding exons. Bottom panels, ratio charts of the MLPA depicting the deletion or duplication of
various exons in the indicated biopsies and patients. An appropriate normal control is also included. The rectangle indicates the exons that had suffered
duplication and deletion.
LuAD, lung adenocarcinoma; LuSCC, lung squamous cell carcinoma; SCLC, small-cell lung cancer; TKI, tyrosine kinase inhibitor.
E. Pros et al. Annals of OncologyMoreover, we show that the LuAD patients who experienced
SCLC/LuSCC transformation after relapse to treatment carried
RB1-inactivated tumors.The cell of origin of some EGFR-mutant
LuADs, type II alveolar cells, also has the potential to become
SCLC, which may explain their capability to transdifferentiate.20
Another important question is whether inactivation of RB1 isVolume 31 - Issue 2 - 2020involved in the acquired resistance to EGFR-TKI treatment.We
found that this alteration could precede the acquisition of
resistance to the TKI, and that SCLC/LuSCC transformation can
be found concomitantly with the acquisition of the EGFR-
T790M mutation or the FGFR3eTACC3 fusion. It was of
particular note that an EGFR-wild-type LuAD also acquiredhttps://doi.org/10.1016/j.annonc.2019.09.001 279
Figure 4. Dissection of the molecular events underlying SCLC/LuSCC transformation during the acquisition of resistance to treatment in LuAD patients. (A) Phase-
contrast images of the indicated patient-derived cancer cells (PDCs), showing the changes in cell morphology between the parental and the indicated resistant cells
(3200 magnification). (B) Colony-formation assay for each indicated PDCs to show cell-growth inhibition upon administering afatinib or erlotinib at the indicated
concentrations. (C) Western blot analysis to show the phosphorylation levels of proteins involved in signal transduction pathways, in the PDC4 and PDC5 cells and
in their corresponding cells after acquisition of resistance to EGFR-TKI (PDC4.2 and PDC5.2). ACTIN, protein-loading control. (D) Western blot analysis of the
indicated proteins in the PDC4 and PDC4.2 cells, upon treatment with EGF (30 nM) at different times with and without afatinib, at the indicated concentrations.
NUCLEOLIN, protein-loading control. (E) Heatmap showing a selection of transcripts that show changes in gene expression, by RNA-seq (normalized counts), in the
indicated PDCs from tumors before and after having acquired resistance to EGFR-TKI. Some of these transcripts are characteristic of LuSCC (underlined) or SCLC (in
blue). The heatmap was generated with MS Excel (Microsoft, Richmond, WA) conditional formatting based on normalized count values; red indicates the
maximum (Max) and light blue the minimum (Min) values.
EGF, epithelial growth factor; LuAD, lung adenocarcinoma; LuSCC, lung squamous cell carcinoma; SCLC, small-cell lung cancer; TKI, tyrosine kinase inhibitor.
Annals of Oncology E. Pros et al.SCLC/LuSCC transformation following chemoradiotherapy.
Collectively, these observations suggest that the inactivation of
RB1, per se, does not confer resistance to EGFR-TKIs or to
standard chemotherapy. Instead, it may favor tumor aggres-
siveness, by promoting cell plasticity and SCLC/LuSCC trans-
formationunder growth-inhibitionpressure, thus facilitating the
rise of cancer cells with resistance-associated mutations.While
the contribution of RB1 inactivation to the acquired resistance
to EGFR-TKIs remains to be fully ascertained, the status ofRB1 in
EGFR-mutant LuADs, including ICRs, may need to be considered
as amarker predicting the riskof LuAD transformation to amore
aggressive type of LC.280 https://doi.org/10.1016/j.annonc.2019.09.001Finally, we observed that a subset of non-smoking-
associated LC patients carries germline heterozygous mu-
tations at autosomal recessive (BLM, FANCL, and WRN) and
at dominant cancer-predisposing genes, especially in TP53.
Although an increased risk of LC in LieFraumeni patients
has been documented, little is known about the accumu-
lation of EGFR-mutant tumors among these patients. Only
some case reports have been published in this regard.21 The
possible familiar aggregation of cancer may need to be
taken into account in NSK-LuADs patients, in order to
identify those individuals who could be offered genetic
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